Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 5, 2003, Pages 457-462

  Boström, Stig L ^a   Hansson, Göran F H ^a   Kjaer, Magnus ^a   Sarich, Troy C ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Direct thrombin inhibitor; Endogenous thrombin potential; Melagatran; Thrombin generation; Ximelagatran

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; XIMELAGATRAN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENDOGENOUS THROMBIN POTENTIAL; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL TECHNOLOGY; NORMAL HUMAN; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBIN GENERATION ASSAY;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; DALTEPARIN; FACTOR XA; GLYCINE; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, SUBCUTANEOUS; MALE; REFERENCE VALUES; THROMBIN; TIME FACTORS; VEINS;

EID: 0038513109     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200307000-00005     Document Type: Article

References (34)

1. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96:2311-2315.
2. Badimon L, Meyer BJ, Badimon JJ. Thrombin in arterial thrombosis. Haemostasis 1994; 24:69-80.
3. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79:110-116.
4. Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360:1441-1447.
5. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347:635-639.
6. Bush LR. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev 1991; 9:247-263.
7. Klement P, Carlsson S, Rak J, Liao P, Vlasin M, Stafford A, et al. The benefit-to-risk profile of melagatran is superior to that of hirudin in rabbit arterial thrombosis prevention and bleeding models. J Thromb Haemost 2003; 1:567-594.
8. Eriksson BI, Arfwidsson A-C, Frison L, Eriksson UG, Bylock A, Kälebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of venous thromboembolism after total hip or total knee replacement: METHRO I. Thromb Haemost 2002; 87:231-237.
9. Eriksson H, Wȧhlander K, Gustafsson D, Welin L, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1:41-47.
10. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, et al., for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161:2215-2221.
11. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137:648-655.
12. Petersen P, Grind M, Adler A, for the SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation - SPORTIF II: a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003; 41:1445-1451.
13. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56:9-17.
14. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70:617-624.
15. Sarich TC, Eriksson UG, Mattsson C, Woltz M, Frison L, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87:300-305.
16. Prasa D, Svendsen L, Sturzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost 1997; 77:496-503.
17. Davidian M, Giltman DM. Nonlinear models for repeated measurement data (monographs on statistics and applied probability). London: Chapman & Hall; 1995.
18. Eriksson UG, Bredberg U, Gislėn K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. Eur J Clin Pharmacol 2003; 59:35-43.
19. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347:561-568.
20. Wolzt M, Eder M, Weltermann A, Entlicher J, Eichler HG, Kyrle PA. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man. Thromb Haemost 1997; 78:876-879.
21. Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC, et al. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry 1992; 31:3998-4003.
22. Bjorquist P, Bostrom S. Determination of the kinetic constants of tissue factor, factor VII, factor VIIIA and antithrombin/heparin using surface plasmon resonance. Thromb Res 1997; 85:225-236.
23. Bouma BN, von dem Borne PA, Meijers JC. Factor XI and protection of the fibrin clot against lysis - a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80:24-27.
24. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64:464-468.
25. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74:1021-1024.
26. Beguin S, Welzel D, Al Dieri R, Hemker HC. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999; 29:170-178.
27. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97:2308-2313.
28. Verstraete M. Heparin and thrombosis: a seventy year long story. Haemostasis 1990; 20(suppl 1):4-11.
29. Dawes J. Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. Acta Chir Scand 1990; 556(suppl):68-74.
30. Elg S, Deinum J. The interaction between captured human thrombin and antithrombin studied by surface plasmon resonance, and the effect of melagatran Spectroscopy 2002; 16:257-270.
31. Prasa D, Svendsen L, Sturzebecher J. Inhibition of thrombin generation in plasma by inhibitors of factor Xa. Thromb Haemost 1997; 78:1215-1220.
32. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995; 6(suppl 1):S7-S13.
33. McVey JH. Tissue factor pathway. Baillieres Best Pract Res Clin Haematol 1999; 12:361-372.
34. Bendz B, Andersen TO, Sandset PM. Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis 2000; 11:343-348.